Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS 443139 in individuals with early manifest Huntington's disease …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• ISIS 443139 (ISIS-443139)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Huntington's Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-05-31